Pre-pectoral AlloDerm® to Reinforce Tissues in Tissue Expander Breast Reconstruction
Pre-pectoral AlloDerm® to Reinforce Tissues in Tissue Expander Breast Reconstruction
Primary Objective:

 • To describe postoperative static pain scores on the Pain Visual Analog Scale at Day 1 in a
 population of women undergoing bilateral mastectomy followed by immediate, bilateral
 pre-pectoral tissue expander breast reconstruction reinforced with AlloDerm® coverage.

 Secondary Objectives:

 -  To describe postoperative static and dynamic pain scores on the Pain Visual Analog Scale
 and Brief Pain Inventory-Short Form at Day 1-60 after tissue expander placement

 -  To describe nausea/vomiting, and opioid use at Day 1, 2, 3, 7, 30, and 60 after
 mastectomy and tissue expander placement.

 -  To describe short-term changes in Quality of Life scores after mastectomy and tissue
 expander placement.

 -  To describe postoperative complication rates at Day 1, 2, 3, 7, 30, and 60 after
 mastectomy and tissue expander placement.

 -  To describe nausea/vomiting, and opioid use at Day 1, 2, 3, 7, 30, and 60 after final
 reconstruction with tissue expander exchange for permanent implant.

 -  To describe short-term changes in Quality of Life scores after final reconstruction with
 tissue expander exchange for permanent implant.

 -  To describe postoperative complication rates at Day 1, 2, 3, 7, 30, and 60 after final
 reconstruction with tissue expander exchange for permanent implant.

 -  To describe postoperative rates of breast animation deformity at Day 7, 30, and 60 after
 final reconstruction with tissue expander exchange for permanent implant.

 -  To describe average hospital length of stay in patients after final reconstruction with
 tissue expander exchange for permanent implant.

 -  To describe the patient's final assessment of pre-pectoral reconstruction from free-form
 text.

 Tertiary Objectives:

 • To measure cosmetic result and associated residual pain with Alloderm® reinforcement of
 breast pocket.
Study participants meeting inclusion criteria will be enrolled prior to surgery. Once the
 patient has been seen by one of the Institutional Review Board (IRB)-approved study
 physicians at the initial clinic visit and informed consent has been obtained, pre-study
 patient-reported outcome (PRO) questionnaires will be distributed and collected by one of the
 IRB-approved healthcare providers (i.e. medical assistant, nurse, nurse-practitioner, or
 plastic surgeon). These questionnaires include the Pain Visual Analog Scale, the Patient Pain
 Assessment Questionnaire which assesses static and dynamic pain as well as nausea and
 interference with sleep, the Subjective Pain Survey, the preoperative Breast-Q:
 Reconstruction Module, the SF-36, and the Brief Pain Inventory-Short Form. Participants will
 then be asked to complete a general patient history form.

 Patients will undergo bilateral mastectomy followed by immediate, bilateral pre-pectoral
 tissue expander breast reconstruction with complete AlloDerm® coverage. Patients who are
 determined to be poor surgical candidates intra-operatively will be excluded from the study
 and receive standard of care reconstruction. All patient-specific surgical details will be
 recorded intra-operatively. See Figure 1 for a schematic of the first stage of
 reconstruction: bilateral mastectomy and tissue expander placement.

 Following the surgery, postoperative pain will be assessed by the Pain Visual Analog Scale
 (VAS), the Patient Pain Assessment Questionnaire, and the Brief Pain Inventory-Short Form
 (BPI-SF); pain medication/opioid use and nausea/vomiting will be assessed by the
 Postoperative nausea and vomiting (PONV) Intensity Scale; and adverse events (AEs)/serious
 adverse events (SAEs) and the occurrence of complications (seroma, hematoma, cellulitis, and
 infection requiring expander removal) will be assessed by staff during the hospital stay (Day
 1, Day 2, Day 3) and on Day 7 (±2 days) when participants return to clinic for the first
 follow-up visit after mastectomy and tissue expander placement. At this visit on Day 7, an
 updated medical history will be completed, pain medication and opioid use will be recorded,
 and participant complications/AEs/SAEs assessed. In order to minimize missing data,
 participants will be educated by an IRB-approved member to complete all possible
 questionnaire items. Furthermore, in order to avoid expectancy-bias, study team members will
 ensure that patients complete the PRO questionnaires before meeting with study healthcare
 providers for all postoperative follow-up appointments. Following the completion of all
 assessments on Day 7, patients will undergo initiation of tissue expander expansion carefully
 recording the rate and volume of fill.

 Longer-term quality-of-life/health outcomes assessments will be performed on postoperative
 Day 30 (±4 days) and Day 60 (±7 days) after the initiation of tissue expander expansion.
 During these visits, pain scores (Pain Visual Analog Scale, Patient Pain Assessment
 Questionnaire, and Brief Pain Inventory-Short Form), pain medication/opioid use,
 postoperative Breast-Q, and SF-36 questionnaires will be administered. Day 60 follow-up is
 included as a tertiary endpoint to capture differences in residual pain. Patients will be
 asked to complete the same questionnaires as at the Day 30 follow-up.

 Following final reconstruction with tissue expander exchange for permanent implant, typically
 three months after mastectomy and tissue expander placement, all PRO questionnaires,
 postoperative static and dynamic pain, nausea/vomiting/opioid use, short-term changes in
 Quality of Life, complication rates, average hospital length of stay and residual pain will
 be assessed. Additionally, on Day 30, and Day 60 after permanent implant placement patients
 will be photographed comparing the breasts at rest and with pectoralis muscle flexion to
 assess for breast animation deformity using the Spear 4-point grading system. They will then
 be imaged using "VECTRA® XT 3D" digital imaging technology ("CANFIELD Scientific", Inc.) on
 Day 60. Differences in breast volume, surface area, shape, size, contour, and symmetry will
 be evaluated using the "VECTRA® XT" Analysis Module software. Day 60 follow-up is included as
 a tertiary endpoint to capture differences in cosmetic result and residual pain after final
 reconstruction. Patients will be asked to complete the same questionnaires as at the Day 30
 follow-up. See Figure 2 for a schematic of the second stage of reconstruction: tissue
 expander exchange for permanent implant.

 *Patients will be called the morning of their Day 7, Day 30, and Day 60 appointments as a
 reminder. In the event they are unable to attend, every attempt will be made to reschedule
 within 2, 4, and 7 days, respectively.
Inclusion Criteria:

 -  Be women, aged 18-75 years.

 -  Choose bilateral mastectomy (therapeutic or prophylactic) followed by immediate,
 bilateral pre-pectoral tissue expander breast reconstruction with complete AlloDerm®
 coverage.

 -  Have no inflammatory breast cancers.

 -  Be aware of the nature of her malignancy.

 -  Understand the study purpose, requirements, and risks.

 -  Be able and willing to give informed consent.

 Exclusion Criteria:

 -  Plan to undergo final reconstruction with autologous material.

 -  Allergies to gentamicin, cefoxitin, lincomycin, vancomycin, or polymixin (antibiotics
 used in the pre-treatment of AlloDerm®).

 -  Active connective tissue disease.

 -  Current smokers.

 -  History of, or plan to undergo irradiation of the breasts.